Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation
Chemistry & Biodiversity · 2025-09 · 22 (9)
DOI: 10.1002/cbdv.202500549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 03.05.2025. Verfasst von Rohit Pal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre, Acharya & BM Reddy College of Pharmacy, Bengaluru, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Pyrimidines, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) mutations, especially in non–small cell lung cancer (NSCLC), present significant challenges to targeted therapies due to acquired resistance. This study reports the synthesis and evaluation of a series of 4‐(2‐substituted‐6‐(furan‐2‐yl)pyrimidin‐4‐yl)‐substituted phenyl derivatives as potential anticancer agents. The compounds were screened using MTT and brine shrimp lethality assays, identifying R2 , R10 , and R12 as the most potent against NSCLC cell lines, particularly NCI‐H522 and NCI‐H1975. Compound R12 was most potent and selective against NCI‐H522, with an IC 50 value of 0.95 ± 0.02 µM as compared to standard afatinib (IC 50 = 1.86 ± 0.22 µM). EGFR inhibition assays confirmed R12 effectiveness with IC 50 values of 1.62 ± 0.15 µM, 0.49 ± 0.23 µM, and 0.98 ± 0.02 µM against EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S , respectively. The compound R12 led to the cell cycle arrest in the G2/M and S phase of NCI‐H522 cells with an increase in apoptosis. Molecular docking studies showed R12 high binding affinity (Δ G = −10.2 kcal/mol for EGFR WT ; K i = 32.73 nM) and significant interactions with key amino acids in the active site. Molecular dynamics simulations demonstrated stable protein–ligand interactions with low RMSD (0.17–0.27 nm) and significant eigenvalue (1.706 × 10 −4 ). Compound R12 also exhibited antioxidant properties against DPPH (IC 50 = 12.11 ± 8.96 µM) and H 2 O 2 (IC 50 = 8.89 ± 1.72 µM). Furthermore, DFT analysis and ADMET predictions indicated that R12 possesses favorable physiochemical and pharmacokinetic properties, suggesting high bioavailability and minimal toxicity. These findings emphasize R12 as a promising lead for further preclinical investigation in overcoming EGFR mutations, including the challenging triple mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre, Acharya & BM Reddy College of Pharmacy, Bengaluru, India.
- School of Pharmacy, Sangam University, Bhilwara, India.
- Department of Pharmaceutical Chemistry, National University of Science and Technology, Muscat, Oman.
- Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, India.
ORCID-Profile: Rohit Pal, Md Jawaid Akhtar
Zitieren
APA
Pal, R., Matada, G. S. P., Teli, G., Akhtar, M. J., & Kumar, B. (2025). Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation. Chemistry & Biodiversity, 22(9). https://doi.org/10.1002/cbdv.202500549
Vancouver
Pal R, Matada GSP, Teli G, Akhtar MJ, Kumar B. Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation. Chemistry & Biodiversity. 2025;22(9). doi:10.1002/cbdv.202500549
BibTeX
@article{Pal2025,
author = {Pal, Rohit and Matada, Gurubasavaraja Swamy Purawarga and Teli, Ghanshyam and Akhtar, Md Jawaid and Kumar, Bhupinder},
title = {Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation},
journal = {Chemistry & Biodiversity},
year = {2025},
volume = {22},
number = {9},
doi = {10.1002/cbdv.202500549}
}
EUVIMED